Nebenwirkungen · Ablymico
Ablymico 6 mg/mL solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 10
HOS-153852 · Präparat HOS-101056
Tachycardia In clinical trials, tachycardia was reported in 0.6 % of patients treated with liraglutide and in 0.1 % of patients treated with placebo. The majority of events were mild or moderate. Events were isolated and the majority resolved during continued treatment with liraglutide.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T17:00:12Z · SHA-256 fb6406a9787e7b91caa53fb08b95f8f4ee77e4d4345da47d2f8b9ae38c38a3d6 · Passage ee7a8212fb4f2089e8ee910863ff5f9008924f4d4036783ad3dac395d1fded7b · Zeichen 8093–8380 im Abschnitt